The study offers guidance to clinicians treating the roughly 10% of patients with rare EGFR mutations. Patients with non–small cell lung cancer (NSCLC) who have uncommon EGFR mutations appear to have ...

A new collaborative study reports the discovery and application of a novel therapeutic strategy to selectively target EGFR ...

H. Jack West, M.D., explains how to best optimize the treatment of EGFR-mutated non-small cell lung cancer by using TKIs. The first-line approach for patients with EGFR-mutated non—small cell lung ...

Christopher Arendt, PhD, head, Oncology Therapeutic Area Unit, Takeda, speaks on the success of tyrosine kinase inhibitors (TKIs) in the treatment of blood cancers and efficacy implications of these ...

From Chemotherapy to Targeted Pills: A New Era in Chronic Myeloid Leukemia and What Asciminib Could Mean for Patients ...

Chinese Medical Journals Publishing House Co., Ltd. Numerous EGFR-TKIs are approved for EGFR-sensitive mutation NSCLC, including gefitinib, erlotinib, icotinib, osimertinib, and 11 others. First-line ...

Patients with advanced renal cell carcinoma who are taking a tyrosine kinase inhibitor (TKI) to prolong their lives will typically keep going without a break until the disease progresses or toxicities ...

TKI-based regimens remain the primary approach for metastatic renal cell carcinoma after immune checkpoint inhibitor therapy, even in later treatment lines. The study involved 293 patients, ...

Sociodemographic and clinicopathological factors affecting survival in young women: Real-world data from Brazil. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Tyrosine kinase inhibitors (TKIs) have recently ...